CORD-19:ee0a7632371a08727d41e55aad7d621daeceef7d / 657832-657960 JSONTXT

{"target":"https://pubannotation.org/docs/sourcedb/CORD-19/sourceid/ee0a7632371a08727d41e55aad7d621daeceef7d","sourcedb":"CORD-19","sourceid":"ee0a7632371a08727d41e55aad7d621daeceef7d","text":"Studies have shown that EGFR monoclonal antibody therapy is unlikely to be beneficial in tumors with any KRAS or NRAS mutations.","tracks":[{"project":"CORD-19-Sentences","denotations":[{"id":"T68815","span":{"begin":0,"end":128},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"attributes":[{"subj":"T68815","pred":"source","obj":"CORD-19-Sentences"}]},{"project":"CORD-19_Custom_license_subset","denotations":[{"id":"T136","span":{"begin":0,"end":128},"obj":"Sentence"}],"attributes":[{"subj":"T136","pred":"source","obj":"CORD-19_Custom_license_subset"}]},{"project":"CORD-19-PD-MONDO","denotations":[{"id":"T3121","span":{"begin":89,"end":95},"obj":"Disease"},{"id":"T55210","span":{"begin":89,"end":95},"obj":"Disease"}],"attributes":[{"id":"A3121","pred":"mondo_id","subj":"T3121","obj":"http://purl.obolibrary.org/obo/MONDO_0005070"},{"id":"A44548","pred":"mondo_id","subj":"T55210","obj":"http://purl.obolibrary.org/obo/MONDO_0005070"},{"subj":"T3121","pred":"source","obj":"CORD-19-PD-MONDO"},{"subj":"T55210","pred":"source","obj":"CORD-19-PD-MONDO"}]}],"config":{"attribute types":[{"pred":"source","value type":"selection","values":[{"id":"CORD-19-Sentences","color":"#93cdec","default":true},{"id":"CORD-19_Custom_license_subset","color":"#e7ec93"},{"id":"CORD-19-PD-MONDO","color":"#d693ec"}]}]}}